Lannett Co Inc (LCI) Social Stream

Lannett Co Inc (LCI): $4.86

-0.31 (-6.00%)

POWR Rating

Component Grades













Featured Post From StockTwits About LCI

$LCI You guys aren't even including the 8 million warrants at $6.80 they had to issue to the existing seems to me, this was a very expensive re-fi, all to free up cashflow (interest only). What does that mean? Who knows.....buying products/company? Won't be a dividend or stock buyback. It must signal FCF from ops is going to be negative while they get through the two big product launches.
crackpot, published April 9, 2021

What Else are LCI Traders Talking About?

Other tickers frequently mentioned alongside LCI are GPRO, IGT, ELAN and TME.

Other Notable StockTweets About LCI

$LCI Wow earnings projected to be negative for the next two quarters. I haven’t been paying much attention to this turd but it stinks worse than ever. I’ve always been able to recover most or all my investment if I just waited patiently for long enough but this company can’t get its shit together. Guess at least the debt is handled for awhile so they can survive to suck another day!

Mactoast, published April 7, 2021

$GPRO $IGT $ELAN $TME $LCI These all had private market orders on Friday (See link below) These orders were all marked as rare and unusual by a computer system. The data is not mine but has been really crucial in my trade plans. The discord has a lot of free channels and good traders in it. Linked in my bio and on the data page.

thowingdarts, published March 21, 2021

$ATNF $ATNF is the most shorted stock in the market compared to float. Short term we have the biggest chance to squeeze and long term we are looking at 20x to 50x gain at a minimum. If this message is showing up on your board you are also under attack by short sellers... Just trying to be a good friend and help you make some money. Come do some DD.


Drunkcowsmoo, published March 11, 2021

Lannett receives feedback from FDA regarding biosimilar insulin glargine Lannett announced that it recently received feedback from the FDA regarding biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies, or HEC. Lannett sought and received comments from the FDA related to the pivotal trial protocol and statistical analysis plan, or SAP, for the development program. At a Biosimilar Biological Product Development, or BPD, Type 2 meeting in June 2020, representatives from Lannett spoke with and received guidance from the FDA on the clinical advancement program of its biosimilar insulin glargine partnered product candidate.
Read more at:
View the full list of news/momentum plays on watch at :
[No bias / position]
[Find me at |]"

sbiswas, published March 10, 2021

Loading social stream, please wait...

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.567 seconds.